Anna Sureda

33.8k total citations · 3 hit papers
465 papers, 11.7k citations indexed

About

Anna Sureda is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Anna Sureda has authored 465 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Oncology, 205 papers in Pathology and Forensic Medicine and 191 papers in Hematology. Recurrent topics in Anna Sureda's work include Lymphoma Diagnosis and Treatment (203 papers), Hematopoietic Stem Cell Transplantation (103 papers) and CAR-T cell therapy research (88 papers). Anna Sureda is often cited by papers focused on Lymphoma Diagnosis and Treatment (203 papers), Hematopoietic Stem Cell Transplantation (103 papers) and CAR-T cell therapy research (88 papers). Anna Sureda collaborates with scholars based in Spain, United Kingdom and France. Anna Sureda's co-authors include Rodrigo Martino, Salut Brunet, Jorge Sierra, Norbert Schmitz, Jakob Passweg, Peter Dreger, Carmen Canals, Rafael F. Duarte, Mohamad Mohty and Helen Baldomero and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anna Sureda

435 papers receiving 11.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Anna Sureda et al. profile →
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Anna Sureda et al. profile →
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

2022 159 citations John A. Snowden, Isabel Sánchez‐Ortega et al. Bone Marrow Transplantation profile →

Peers

Countries citing papers authored by Anna Sureda

Since Specialization

Citations

This map shows the geographic impact of Anna Sureda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Sureda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Sureda more than expected).

Fields of papers citing papers by Anna Sureda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Sureda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Sureda. The network helps show where Anna Sureda may publish in the future.

Co-authorship network of co-authors of Anna Sureda

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Sureda. A scholar is included among the top collaborators of Anna Sureda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Sureda. Anna Sureda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP 2026 ·Bone Marrow Transplantation ·(unknown), Ali Bazarbachi, Ambroise Marçais, (unknown), (unknown), Arian Laurence, Victoria Potter, (unknown), (unknown), Lucy Cook, (unknown), Emma Nicholson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anna Sureda	0
2	Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial 2025 ·Journal of Clinical Oncology ·Martin Hutchings, Anna Sureda, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, Abraham Avigdor, María José Terol, Antonio Rueda‐Domínguez, Antonio Pinto, Alan P Skarbnik, Raúl Córdoba, Judit Jørgensen, Pier Luigi Zinzani, Wilfred Leung, Alessia Bottos, (unknown), James Relf, Maneesh Tandon, Gila Sellam, Giuseppe Gritti	0
3	Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study 2024 ·Blood Advances ·Simon Renders, (unknown), Hervé Finel, (unknown), William Townsend, Roland Schroers, Urban Novak, Nicolaas Schaap, Mahmoud Aljurf, Grzegorz Helbig, Matthew Collin, (unknown), (unknown), Josè Antonio Pérez-Simón, Adrian Bloor, Hervé Ghesquières, Anna Sureda, Norbert Schmitz, Bertram Glaß, Peter Dreger	0
4	Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial 2024 ·Clinical Microbiology and Infection ·Júlia Laporte-Amargós, Francisco Carmona-Torre, (unknown), Pedro Puerta‐Alcalde, Raül Rigo‐Bonnin, Marta Ulldemolins, Montserrat Arnán, José Luís del Pozo, Anna Torrent, Carolina García‐Vidal, Natàlia Pallarés, Cristian Tebé, Carmen Muñoz, Fé Tubau, Ariadna Padullés, Anna Sureda, Jordi Carratalà, Carlota Gudiol	1
5	Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) 2024 ·Cytotherapy ·Fermín Sánchez‐Guijo, Joaquim Vives, (unknown), Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Dominique Farge, Nico Gagelmann, (unknown), Jürgen Kuball, Bénédicte Neven, (unknown), Vanderson Rocha, Isabel Sánchez‐Ortega, John A. Snowden, Jaap Jan Zwaginga, Massimiliano Gnecchi, Anna Sureda	10
6	CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern? 2023 ·Frontiers in Neurology ·Roser Velasco, Alberto Mussetti, Macarena Villagrán‐García, Anna Sureda	32
7	Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey 2023 ·Bone Marrow Transplantation ·Jakob Passweg, Helen Baldomero, Fabio Ciceri, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glaß, Raffaella Greco, Donal P. McLornan, Bénédicte Neven, Régis Peffault de Latour, Zinaida Perić, Annalisa Ruggeri, John A. Snowden, Anna Sureda	35
8	Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy 2023 ·Bone Marrow Transplantation ·Ibrahim Yakoub‐Agha, Raffaella Greco, Francesco Onida, Rafael de la Cámara, Fabio Ciceri, Selim Corbacioglu, Harry Dolstra, Bertram Glaß, Michelle Kenyon, Donal P. McLornan, Bénédicte Neven, Régis Peffault de Latour, Zinaida Perić, Annalisa Ruggeri, John A. Snowden, Anna Sureda, Isabel Sánchez‐Ortega	10
9	American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting 2023 ·Transplantation and Cellular Therapy ·Shinichiro Okamoto, Minako Iida, Nada Hamad, Fernando Barroso Duarte, Anna Sureda, Alok Srivastava, Sebastián Galeano, Nelson J. Chao, Damiano Rondelli, Mary E.D. Flowers	2
10	The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P601- P606) 2022 ·Bone Marrow Transplantation ·Murat Kara, Sara González, (unknown), Alberto Mussetti, Annalisa Paviglianiti, (unknown), Anna Sureda	0
11	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey 2022 ·Bone Marrow Transplantation ·Jakob Passweg, Helen Baldomero, Christian Chabannon, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glaß, Raffaella Greco, Mohamad Mohty, Bénédicte Neven, Régis Peffault de Latour, Zinaida Perić, John A. Snowden, Ibrahim Yakoub‐Agha, Anna Sureda, Nicolaus Kröger, (unknown)	41
12	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) 2021 ·Blood ·Franck Morschhauser, Carmelo Carlo‐Stella, Michael Dickinson, Tycel Phillips, Roch Houot, Fritz Offner, Corinne Haïoun, Paolo Corradini, Martin Hutchings, Anna Sureda, Joaquín Martínez‐López, Tomasz Wróbel, Shang‐Ju Wu, Linda Lundberg, (unknown), David Pérez-Callejo, James Relf, Anesh Panchal, Kathryn Humphrey, Emmanuel Bachy	20
13	Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy 2021 ·Cancers ·Roser Velasco, Eva Domingo‐Doménech, Anna Sureda	23
14	Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience 2021 ·Hematology Transfusion and Cell Therapy ·María Queralt Salas, Alberto Mussetti, Carmen Muñoz, Adaia Albasanz‐Puig, Beatriz Patiño, (unknown), Carlota Gudiol, Rocío Parody, Anna Sureda	3
15	Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19 2021 ·Blood Advances ·José Luís Piñana, Ramón García‐Sánz, Rodrigo Martino, (unknown), (unknown), (unknown), Mar Tormo, Pilar Martinez‐Barranco, (unknown), Marisa Calabuig, (unknown), Anabel Teruel, (unknown), Carlos Solano, David Navarro, Ángel Cedillo, Anna Sureda	2
16	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome 2017 ·Hematological Oncology ·Marc Sorigué, Santiago Mercadal, Sara Alonso, Rubén Fernández-Álvarez, Olga García, (unknown), Helena Pomares, Miguel Alcoceba, (unknown), (unknown), Eva González‐Barca, Alejandro Martı́n, Anna Sureda, Dolores Caballero, Josep‐María Ribera, Juan‐Manuel Sancho	11
17	Invasive fungal infections in AML / MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? 2016 ·Mycoses ·Helena Pomares, Montserrat Arnán, Isabel Sánchez‐Ortega, Anna Sureda, Rafael F. Duarte	36
18	Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL): Results from the UK Phase II Mini Allo Study (CRUK: C7627/A9080) 2016 ·UCL Discovery (University College London) ·(unknown), K Peggs, Gary Cook, NH Russell, Anne Hunter, Simon P. Robinson, (unknown), Anna Sureda, (unknown), Pip Patrick, (unknown), Lindsey Stevens, (unknown), (unknown), Simon Rule	2
19	Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry 2011 ·Journal of Clinical Oncology ·Roel J.W. van Kampen, Carmen Canals, Harry C. Schouten, Arnon Nagler, Kirsty Thomson, (unknown), Agnès Buzyn, Marc Boogaerts, J.J. Luan, Sébastien Maury, Nöel Milpied, (unknown), Gert J. Ossenkoppele, Anna Sureda	141
20	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival 2008 ·Journal of Clinical Oncology ·Juan José Lahuerta, María‐Victoria Mateos, Joaquín Martínez‐López, Laura Rosiñol, Anna Sureda, Javier de la Rubia, José García‐Laraña, Rafael Martínez-Martinez, Miguel Teodoro Hernández‐Garcia, Dolores Carrera, Joan Besalduch, Felipe de Arriba, Josep‐María Ribera, Lourdes Escoda, (unknown), Javier García‐Frade, (unknown), Adrían Alegre, Joan Bladé, Jesús F. San Miguel	193

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact